<DOC>
	<DOC>NCT01299584</DOC>
	<brief_summary>This study is a post-marketing surveillance to monitor safety and efficacy of remifentanil during various surgeries and identify SAEs, adverse drug reactions, and unexpected AEs not described as precautions or warnings and to identify prognostic factors that have an effect on the AEs and to assess effectiveness of remifentanil in real clinical practices after marketing. The subjects are patients prescribed for remifentanil by the investigators at the sites based on prescription information in normal clinical practices.</brief_summary>
	<brief_title>ULTIVA Post Marketing Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Remifentanil</mesh_term>
	<criteria>Patients requiring general anesthesia According to precautions or warnings on PI, remifentanil should not be administered to the following patients Patients with any allergic reaction to any ingredients of remifentanil or other fentanyl analogues</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>